Perrigo's 'Inversion' Of Flonase Trademark Cuts Too Close For Glaxo's Market Share Comfort
This article was originally published in The Tan Sheet
Executive Summary
Glaxo says it distributed more than $330m in Flonase Allergy Relief in 2015, its first year available as the second-in-category corticosteroid nasal spray, but argues that Nasoflow, Perrigo's brand for a generic equivalent, unfairly will encroach on its sales and market share.
You may also be interested in...
Bayer Fortifies Branding In OTC Naproxen Market With Win In Trademark Litigation
Bayer convinces federal court to affirm USPTO appeal board decision to cancel competitor Belmora’s Flanax US naproxen product trademark because the firm used packaging that resembled a Bayer product with the same name sold in Mexico. The ruling could provide standing for owners of foreign marks to assert priority rights over similar US marks, according to a patent attorney.
Bayer Fortifies Branding In OTC Naproxen Market With Win In Trademark Litigation
Bayer convinces federal court to affirm USPTO appeal board decision to cancel competitor Belmora’s Flanax US naproxen product trademark because the firm used packaging that resembled a Bayer product with the same name sold in Mexico. The ruling could provide standing for owners of foreign marks to assert priority rights over similar US marks, according to a patent attorney.
Perrigo Nutritional Portfolio Grows As Supplement Business Sale Proceeds
Perrigo launches the first generic of Abbott's Ensure Glucerna nutritional shake. The launch could be seen as another potential jolt to lift Perrigo's share price out of a year-long fall that began when Mylan opened its unsuccessful hostile takeover.